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Abstract
Background: Biomarkers for predicting late normal tissue toxicity to radiotherapy are necessary to personalize
treatments and to optimize clinical benefit. Many radiogenomic studies have been published on this topic.
Conversely, proteomics approaches are not much developed, despite their advantages.
Methods: We used the isobaric tags for relative and absolute quantitation (iTRAQ) proteomic approach to analyze
differences in protein expression levels in ex-vivo irradiated (8 Gy) T lymphocytes from patients with grade ≥ 2
radiation-induced breast fibrosis (grade ≥ 2 bf+) and patients with grade < 2 bf + after curative intent radiotherapy.
Patients were selected from two prospective clinical trials (COHORT and PHRC 2005) and were used as discovery
and confirmation cohorts.
Results: Among the 1979 quantified proteins, 23 fulfilled our stringent biological criteria. Immunoblotting analysis
of four of these candidate proteins (adenylate kinase 2, AK2; annexin A1; heat shock cognate 71 kDa protein; and
isocitrate dehydrogenase 2) confirmed AK2 overexpression in 8 Gy-irradiated T lymphocytes from patients with
grade ≥ 2 bf + compared with patients with grade < 2 bf+. As these candidate proteins are involved in oxidative
stress regulation, we also evaluated radiation-induced reactive oxygen species (ROS) production in peripheral blood
mononuclear cells from patients with grade ≥ 2 bf + and grade < 2 bf+. Total ROS level, and especially superoxide
anion level, increased upon ex-vivo 8 Gy-irradiation in all patients. Analysis of NADPH oxidases (NOXs), a major
source of superoxide ion in the cell, showed a significant increase of NOX4 mRNA and protein levels after
irradiation in both patient groups. Conversely, only NOX4 mRNA level was significantly different between groups
(grade ≥ 2 bf + and grade < 2 bf+).
Conclusion: These findings identify AK2 as a potential radiosensitivity candidate biomarker. Overall, our proteomic
approach highlights the important role of oxidative stress in late radiation-induced toxicity, and paves the way for
additional studies on NOXs and superoxide ion metabolism.
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Background
Nowadays, radiation therapy (RT) is a major cancer
treatment, and approximately 50–60% of patients
undergo RT after primary cancer diagnosis [1]. Its
success depends mainly on the total radiation dose
homogeneously delivered within the target volume.
However, RT use for cancer treatment inevitably in-
volves exposure of the surrounding normal tissues, and
may cause late and irreversible toxicities. Stratifying pa-
tients according to their risk level for such toxicities and
modulating radiation dose in function of the sensitivity
of the surrounding normal tissues would provide an in-
valuable tool for personalized RT and long-term patient
management [2].
Many efforts have been made to develop assays to pre-
dict susceptibility to radiation injury with the ultimate
objective of personalizing RT protocols [3, 4]. One of
the most promising approaches for clinical use is the ra-
diation-induced CD8 lymphocyte apoptosis (RILA) assay
developed by our group several years ago [5, 6]. This
assay is based on the measurement of the radiation-in-
duced apoptosis rate in T lymphocytes isolated from a
whole blood sample, 2 days after ex-vivo exposure to 8
Gy of radiation. Although RILA displays a low positive
predictive value, its sensitivity and negative predictive
value are high. Indeed, we and others consistently re-
ported low RILA values in all patients with radiation-in-
duced late toxicity, and high RILA values in all patients
without late toxicities [7–10].
Many proteomics studies have shown proteome
changes after irradiation; however, only few of them cor-
related these changes with radiation toxicity, especially
in humans. Indeed, several models (in vitro, animals,
humans, etc.) allowed the identification of radiation-in-
duced alterations in the protein levels of tissues and bio-
fluids, but only focused on dose- or time-related effects
[11]. Other studies investigated protein expression
changes in association with response to RT and tumor
radioresistance in head and neck, breast, lung, and pros-
tate cancer [12–19]. Overall, RT-induced proteome
changes and their possible implication as predictors of ra-
diation disease have been extensively reviewed [20–22].
However, due to the lack of clinical data and access to
samples, few proteomic-based studies could identify hu-
man biomarkers predictive of radiation-induced damage
in normal tissue. Only targeted proteomic approaches
demonstrated the interest of plasma cytokines, par-
ticularly TGF-β1 [23–26], for the prediction of radi-
ation-induced lung toxicity, although this is still a
matter of debate [27, 28]. In the present study, we
wanted to identify and characterize candidate proteins
that might predict the risk of occurrence of grade ≥ 2
radiation-induced breast fibrosis after curative-intent
RT. To this aim, we used the isobaric tags for relative
and absolute quantitation (iTRAQ) proteomic ap-
proach and ex-vivo irradiated T lymphocytes (same
protocol as for the RILA assay) from patients with
grade ≥ 2 and with grade < 2 radiation-induced breast
fibrosis. Overall, this approach revealed that oxidative
stress may contribute to the mechanisms involved in
the development of late radiation-induced toxicity.
Methods
Patient selection and toxicity assessment
Patients were selected from two prospective clinical tri-
als (COHORT and PHRC 2005) and accepted to partici-
pate to this translational sub-study initially planned in
both protocols. These trials were approved by our local
ethics committee and registered at clinicaltrials.gov
(NCT00208273 and NCT00893035, respectively). Skin
toxicity was assessed according to the Common Toxicity
Criteria Adverse Event version 3.0 (CTCAE v3.0) (11) at
baseline, every week during radiotherapy, 3–6 weeks
after the last radiotherapy fraction, every 3 months up to
month 24, every 6 months during the first 3 years, and
every year thereafter. Breast fibrosis was evaluated (as
the primary endpoint) in 150 (phase II randomized CO-
HORT study) and 502 (longitudinal PHRC 2005 trial)
women with stage I-II breast cancer treated by adjuvant
radiotherapy (7, 8). Consecutive patients who presented
with late radiation-induced toxicity were selected and
asked to participate to this study. In regards to the pa-
tients presenting no toxicity, the selection was made by
performing a statistical match with the patients present-
ing toxicities, based on their clinical and treatment
characteristic and RILA values. In both studies, patients
underwent breast-conserving surgery with sentinel node
biopsy and with or without axillary dissection. Before
any adjuvant treatment, the RILA assay was performed
for all patients. For this study, a total of 30 patients were
selected within the follow-up period: two patients who
developed grade ≥ 2 radiation-induced sub-cutaneous
breast fibrosis (bf+) with low RILA score (≤16%) in the
COHORT trial (discovery and confirmation sets); five
patients with grade ≥ 2 bf + and low RILA score (≤16%)
in the PHRC 2005 study (confirmation set); and 23 pa-
tients (COHORT and PHRC 2005) without grade ≥ 2
bf + and low (≤16%, n = 13) or high RILA score (> 16%;
n = 10). Clinical information on these 30 patients is in
Additional file 1: Table S1. Blood samples were collected
in BD Vacutainer EDTA tubes. All samples were proc-
essed and stored in Montpellier (France).
Proteomics analysis
Experimental design
The experimental design used for the iTRAQ-based
quantitative proteomic analysis is illustrated in Fig. 1a.
For the discovery stage, four patients with low RILA
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score (≤16%) were selected: two patients who developed
grade ≥ 2 bf + 2 years after RT end, and two patients
without any toxicity 4 years after RT end. Two technical
replicates were performed for the mass spectrometry
analysis. To identify new radiosensitivity biomarkers,
first protein expression levels were compared in ex-vivo
irradiated (8 Gy) T lymphocytes from these two groups
of patients. Then, among the proteins that were differen-
tially expressed (i.e., potential markers), the analysis fo-
cused on proteins the expression of which was
modulated by ex-vivo irradiation (8 Gy) after comparison
with non-irradiated (0 Gy) paired samples.
Sample preparation
T lymphocytes were purified immediately after collec-
tion by negative selection (RosetteSep, StemCell Tech-
nologies) from whole blood, and cultured in 6-well
plates (4 × 106 cells per well) in growth medium (RPMI
medium containing 20% fetal bovine serum [FBS]) for
24 h. Then, half of each cell sample was irradiated ex-
vivo (8 Gy), as done for the RILA assay (8). Forty-eight
hours after irradiation, subcellular fractionation (cyto-
solic, membrane/organelle and nucleic fractions) was
performed using the ProteoExtract Subcellular Proteome
Extraction Kit (Calbiochem), according to the manufac-
turer’s recommendations and using the fraction-specific
buffers provided in the kit. Protein concentration was
measured with the Micro BCA Kit (Pierce).
iTRAQ labeling and peptide processing
iTRAQ labeling was performed according to the manu-
facturer’s protocol (AB Sciex). Briefly, 50 μg of proteins
from each fraction was precipitated using four volumes
of acetone. Pelleted proteins were dissolved in 500 mM
triethylammonium bicarbonate/1% SDS. Proteins were
reduced with 5 mM tris-(2-carboxyethyl) phosphine,
alkylated with 10 mM methyl methanethiosulfonate, and
digested with trypsin overnight. The resulting peptides
were labeled by incubation with one of the eight isobaric
amine-reactive tags for 2 h. Labeled peptides were com-
bined and cleaned using a strong cation exchange cart-
ridge, as recommended by the manufacturer (AB Sciex).
Fig. 1 Quantitative Proteomic Analysis. a Schematic overview of the strategy used for the iTRAQ analysis. b Venn diagram showing the
distribution of the 1979 identified proteins in each subcellular fraction. c Heat map and patient clustering according to the protein expression
profiles. Each row represents one protein; columns represent the T lymphocyte samples of patients with (n = 2) and without (n = 2) grade≥ 2
bf + after irradiation (8 Gy) or not (0 Gy). In a: eliminate population, change into T lymphocytes
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The strong cation exchange eluents were desalted using
an Oasis HLB extraction cartridge (Waters Corporation)
and vacuum-dried before isoelectric focusing separation
of peptides using the Agilent 3100 OFFGEL Fractionator
(Agilent). Briefly, one IPG DryStrip (24 cm, pH 3–10)
was rehydrated with 20ml/well of a solution containing
0.25% IPG buffer, pH 3–10 (GE Healthcare), for 15 min.
Desalted peptides were dissolved in 0.25% IPG buffer,
pH 3–10, and the peptide solution (150 ml) was pipetted
into each well (24 wells). Isoelectric focusing separation
was performed at 50 kVh, with a maximum current of
50 mA and power of 200mW. Fractions were purified
using OMIX C18 100 ml pipette tips (Varian). Then,
peptides were eluted and lyophilized before reconstitu-
tion for the 2D nano-LC/MS/MS analysis.
Mass spectrometry analysis
Peptides were separated using an Acclaim PepMapTM
(C18, 3 μm, 100 Å), 75 μm/15 cm column (Dionex—LC
Packing) and the Ultimate 3000 nano-LC system
coupled to a ProbotTM Microfraction Collector (Dio-
nex). The used mobile phases were: 2% ACN with 0.05%
TFA (A), and 80% ACN with 0.05% TFA (B). The gradi-
ent elution steps were performed with a flow rate of 0.3
ml/min as follows: 0–50% B for 60min, 50–80% B for
30min, 80–100% B for 5 min, and then 100% B for 10
min. Fractions were mixed directly with the MALDI
matrix solution (2 mg/ml acyano-4-hydroxycinnamic
acid in 70% ACN with 0.1% TFA) at a flow rate of 1.2
ml/min. Fractions were spotted onto the Opti-TOFTM
LC/MALDI insert plates (AB Sciex) using the Probot
spotting device during 110 min at a speed of 11 s per
well. Plates were analyzed using a MALDI TOF/TOF
4800 mass spectrometer (AB Sciex). MS spectra from
m/z 700 to 4000 were acquired in positive reflector ion
mode using 1500 laser shots. The 10 most abundant
peptide precursor ions with signal-to-noise ratios higher
or equal to 50 were selected for MS/MS analysis using
3500 laser shots from m/z 300–1500.
Data analysis
Protein identification and quantification were performed
with the ProteinPilotTM software 2.0.1 and the Paragon
method (AB Sciex). The obtained MS/MS spectra were
searched against the UniProtKB/Swiss-Prot database (re-
lease version 2010_08, http://www.uniprot.org). The
search parameters for tryptic cleavage and accuracy were
built-in functions of the software. The other data
analysis parameters were as follows: 8-plex iTRAQ
peptide labeling, cys-alkylation by MMTS, biological
modifications, and a thorough identification search. The
local false discovery rate (FDR) was estimated using the
Proteomics System Performance Evaluation Pipeline
(PSPEP) tool. Proteins containing one or more peptides
with high confidence score (> 95%) and low FDR (esti-
mated local FDR of 5%) were considered positively iden-
tified. iTRAQ labeling followed by nano-LC MS/MS
analysis was repeated in duplicate to reduce the effect of
experimental variation.
Statistical analysis and gene ontology analysis
The following criteria were required to select a protein
for further analysis: two or more unique peptides with a
high confidence score (> 99%), a p-value for protein
quantification assigned by the ProteinPilot software <
0.05, and > 1.5-fold difference relative to the control
sample. For this discovery phase, the p-value was not
corrected with a more stringent statistical analysis, such
as adjustment for multiple testing, and the risk for false
discovery association still existed at this step. The gene
ontology (GO) classification was determined using the
DAVID bioinformatics resources (12). Statistical signifi-
cance was determined using GraphPad Prism version
7.00 for Windows, GraphPad Software, La Jolla Califor-
nia USA, www.graphpad.com.
Immunoblotting
For the confirmation by western blot analysis, blood
samples from five patients with grade < 2 bf + and five
patients with grade ≥ 2 bf + were included. Because of
the limited number of patients with grade ≥ 2 bf+, the
two patients used in the discovery phase were also in-
cluded in this analysis. Whole blood samples were
treated as described for the quantitative proteomic ana-
lysis except for protein extraction that was performed
using the radioimmunoprecipitation assay (RIPA) buffer.
Proteins were eluted by adding 100 μl 2× SDS-PAGE
buffer, and heated at 95 °C for 10 min. Samples were
size-separated by electrophoresis on SDS-polyacrylamide
gels (12%), and transferred to PVDF membranes (Invi-
trogen). Membranes were blocked with PBST (PBS plus
0.1% Tween-20) containing 5% non-fat milk at 25 °C for
60 min. Blots were then incubated (4 °C, overnight) with
primary antibodies against adenylate kinase 2 (AK2) (1/
100, sc-28,786; Santa Cruz Biotechnology), annexin A1
(ANXA1) (1/100, sc-11,387; Santa Cruz Biotechnology),
galectin-1 (LSGAL1) (1/100, sc-19,277; Santa Cruz Bio-
technology), heat shock cognate 71 kDa protein (HSPA8)
(1/500, sc-7298; Santa Cruz Biotechnology) and isoci-
trate dehydrogenase 2 (IDH2) (1/200, sc-134,923; Santa
Cruz Biotechnology). After five washes (5 min/each) with
PBST, blots were incubated with an anti-rabbit HRP-
conjugated antibody (1:2500, Invitrogen), or an anti-
mouse HRP-conjugated antibody (1:10000, Jackson
ImmunoResearch) at 25 °C for 1 h. After washing five
times at 25 °C with PBST (5 min/each), blots were
developed with ECL Plus (Amersham). β–actin was used
as loading control (1/500, sc-47,778, Santa Cruz
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Biotechnology). Differences between experimental con-
ditions for immunoblotting results were analyzed using
the Mann-Whitney test. P values < 0.05 were considered
statistically significant.
Functional analysis
Peripheral blood mononuclear cell (PBMC) isolation
Whole blood samples were collected in EDTA Vacutainer
tubes from 20 patients: 7 with grade ≥ 2 bf + (including
the 5 patients from the proteomics analysis/immunoblot-
ting) and 13 patients with grade < 2 bf+. PBMCs were
immediately purified by density gradient centrifugation
(Ficoll-Paque PLUS, GE Healthcare Life Sciences) accord-
ing to the manufacturer’s recommendations.
ROS and superoxide anion quantification
PBMCs were resuspended in RPMI-1640 medium
(Sigma) with 20% FBS, and seeded in 6-well plates at a
concentration of 4 × 106 cells per well. The day after, half
of the plates were irradiated (8 Gy). At 6, 24, 48, 72 h
and 120 h after irradiation, the production of ROS–RNS
and superoxide anion in irradiated and control (0 Gy)
cells was measured using the Total ROS/Superoxide De-
tection Kit (Enzo Life Sciences AG) with a slight modifi-
cation of the fluorescence microplate assay protocol for
cells in suspension. Briefly, 1 × 106 cells were washed
once, and incubated in 1 ml of buffer containing 2 μM
oxidative stress detection reagent (green) and 2 μM
superoxide detection reagent (orange) for 60 min. Then,
100 μl of cell-containing mixture was seeded in 96-well
black plates (7 aliquots for each sample), and fluores-
cence was quantified as described in the original proto-
col. Cell number and viability were assessed with the
trypan-blue dye-exclusion assay.
Total RNA extraction and quantitative RT-PCR analysis
Total RNA was purified from PBMCs 24 h after irradi-
ation using the RNAeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. RNA quantity was
assessed with a NanoDrop 2000 Spectrophotometer
(ThermoScientific). For first-strand cDNA synthesis,
500 ng of RNA in 12 μl of RNase-free water was denatu-
rated at 65 °C for 10 min. Then, 2 μl of 10× first-strand
buffer, 2 μl of 5 mM dNTPs, 0.4 μl oligodT (50 μM), 40
UI of RNaseOUT Recombinant Ribonuclease Inhibitor
(Invitrogen, Carlsbad, CA, USA), and 200 Units of
Superscript III (Invitrogen) were added to a total volume
of 20 μl. The mixture was incubated at 37 °C for 60 min,
and then at 95 °C for 5 min. Complementary DNA was
frozen at − 20 °C until use. Real-time quantitative PCR
(qRT-PCR) was performed with the LightCycler 480
SYBR Green I Master system (Roche Applied Science) in
a final volume of 10 μl, including 0.5 μl of each primer
(0.25 μM), 5 μl of the supplied enzyme mix, 3 μl of H2O,
and 1 μl of template (1:20 dilution). After pre-incubation
at 95 °C, 45 cycles were run as follows: 95 °C for 15 s,
60 °C for 20s, and 72 °C for 10s. All samples were run in
triplicate in 384-well optical PCR plates (Roche Diagnos-
tics). Each PCR run included a no-template control
(water added instead of cDNA). For each gene, all sam-
ples were tested in the same plate. The melting curves
of the PCR products were analyzed using the
LightCycler software to exclude amplification of non-
specific products. Results were normalized to the RS9
and β2-microglobulin housekeeping gene transcripts
(Additional file 2: Table S2). Differences in NADPH
oxidase (NOX) mRNA levels between control (0 Gy)
and irradiated (8 Gy) samples were analyzed with the
Wilcoxon matched-pairs signed rank test, whereas dif-
ferences between patient groups were analyzed with
the two-way analysis of variance (ANOVA) with the
Bonferroni post hoc test. For all figures in which
error bars are shown, data represent the mean ± SEM.
Statistical outliers and specimens with measurement
errors were excluded.
Immunoblotting
Protein extraction from PBMCs and western blot ana-
lysis were performed following the same protocol used
for the proteomics analysis confirmation. PVDF mem-
branes were incubated with an anti-NOX4 antibody (1/
200, sc-30,141; Santa Cruz Biotechnology). NOX4 level
was normalized to β-actin level and differences between
groups were analyzed using the paired t-test.
Results
Identification and quantification of differentially
expressed proteins in patients with and without grade ≥
2 breast fibrosis (bf+).
To identify proteins that might predict the risk of
grade ≥ 2 bf+, we compared the proteomic data of
control (0 Gy) and irradiated (8 Gy) T lymphocytes
from patients with (n = 2) and without (n = 2) grade ≥
2 bf + obtained by 2D nano-LC/MS/MS analysis after
iTRAQ labeling. The proteomic workflow is shown in
Fig. 1a. We also performed subcellular fractionation
to maximize the likelihood of identifying proteins.
Using stringent criteria, including one or more pep-
tides with a > 95% confidence score and 5% local
FDR, we identified 1110, 984 and 884 proteins in the
cytosolic, membrane and nucleic fraction, respectively
(Fig. 1b), of which 263 were shared by the three sub-
cellular fractions. In total, we identified and quantified
1979 non-redundant proteins for comparison between
patients with or without grade ≥ 2 bf + (Fig. 1c). We
classified (subcellular distribution and biological pro-
cesses) these 1979 proteins using the GO classifica-
tion system. Specifically, 33% of the identified
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proteins were cytoplasmic proteins, 27% were mem-
brane proteins, 23% were nuclear proteins, 11% were
mitochondrial proteins, and 6% were cytoskeletal pro-
teins (Additional file 3: Figure S1A). We also assessed
the subcellular distribution of the different fractions
to confirm the specific protein enrichment for each
fraction (Additional file 4: Figure S2). Proteins were
associated with a broad range of biological processes
(Additional file 3: Figure S1B): 23% of proteins were
involved in regulation of biological processes, 19% in
response to stimulus, 13% in metabolic processes, and
12% in cell communication. The other proteins were
associated with various cellular functions, including
immune system response, transcription, transport, cell
death, and oxidation-reduction processes. We then
compared the expression profile of these 1979 unique
proteins in each control (0 Gy) and irradiated (8 Gy)
sample pair from patients with and without grade ≥ 2
bf + to identify differentially expressed proteins related
to late radiation toxicity. First, we selected proteins
using stringent biological selection criteria: i) proteins
identified with at least two peptides with high confi-
dence (99%); and ii) proteins significantly (p-value
< 0.05) and differentially (fold-change ≥1.5 or ≤ 0.66)
expressed in irradiated T lymphocytes of the two pa-
tients with grade ≥ 2 bf + relative to the irradiated
samples from the two patients without grade ≥ 2 bf+.
These criteria were fulfilled by 23 proteins, mainly in-
volved in oxidation-reduction processes and RNA
processing (Additional file 5: Figure S3). Then, among
these 23 proteins, we selected 5 proteins with high 8
Gy/0 Gy ratio in the two patients with grade ≥ 2 bf +
relative to the two patients without grade ≥ 2 bf+: ad-
enylate kinase 2 (AK2), annexin A1 (ANXA1), galec-
tin-1 (LSGAL1), heat shock cognate 71 kDa protein
(HSPA8), and isocitrate dehydrogenase 2 (IDH2)
(Additional file 6: Table S3).
Confirmation of the iTRAQ data by western blotting and
qRT-PCR analysis
To confirm the proteomic results, we assessed (west-
ern blotting) AK2, ANXA1, HSPA8, IDH2 and
LSGAL1 expression in control (0 Gy) and irradiated
(8 Gy) T lymphocytes from five patients with grade ≥
2 bf + and five patients with grade < 2 bf + (Fig. 2a).
Unfortunately, we could not quantify LSGAL1 expres-
sion due to antibody malfunction. This analysis
showed that only AK2 (p = 0.0419) was significantly
overexpressed in irradiated samples from both patient
groups (Fig. 2b). Conversely, AK2 mRNA level was
comparable between groups, supporting the hypoth-
esis of a role of protein stability rather than a tran-
scriptomic effect in late toxicity (Additional file 7:
Figure S4).
Free radical level and NADPH oxidase quantification in
PBMCs
Our proteomic analysis revealed that many proteins in-
volved in oxidative stress regulation were differentially
expressed between patients with and without grade ≥ 2
bf+. Oxidative stress and especially free radicals are in-
duced by ionizing radiation and contribute to radiation
injury [29]. Therefore, we quantified the total intracellu-
lar level of ROS and superoxide ion using a specific cell-
permeable fluorescent probe. Due to the limited amount
of blood samples and the need of an important number
of cells for this experiment, we isolated PBMCs instead
of T lymphocytes from 20 patients (n = 7 with grade ≥ 2
bf + and n = 13 with grade < 2 bf+). We measured ROS
and superoxide ion levels at different time points (from
6 to 120 h) after irradiation. As expected, total ROS level
and especially superoxide anion increased progressively
after ex-vivo irradiation (Additional file 8: Figure S5) in
all patients. However, total ROS and superoxide anion
levels were not different between patients with grade ≥ 2
bf + and grade < 2 bf+, with the exception of a slight in-
crease of total ROS level at 72 h after irradiation in
patients with grade ≥ 2 bf + (Additional file 9: Figure S6).
In cells, superoxide anion production is mainly
catalyzed by NOXs through dioxygen reduction [30].
Therefore, we investigated the potential role of the
superoxide-generating NOX family by measuring NOXs
mRNA levels in PBMCs. Among all the tested iso-
forms, NOX4 was the most abundantly expressed in
control (0 Gy) (Fig. 3a) and irradiated (8 Gy) PBMC
samples (Additional file 10: Figure S7). Comparison of
NOX4 mRNAs expression in control (0 Gy) and irra-
diated (8 Gy) PBMCs from all patients together
showed a significant increase after irradiation (p =
0.0027) (Fig. 3b). NOX4 protein level also was
increased after irradiation (p = 0.0153) (Fig. 3c-d).
However, only NOX4 mRNA (but not protein) in-
crease after irradiation was significantly higher in pa-
tients with grade ≥ 2 bf + than in patients with
grade < 2 bf + (p = 0.022, Fig. 4a-b).
Discussion
Although tumor radioresistance has been widely investi-
gated, few studies have considered normal tissue radio-
sensitivity, which is a key factor in RT success [31].
Despite their numerous benefits, proteomic approaches
for studying late radiation-induced toxicity have not
been widely developed [31]. Some studies in animal
models investigated proteome changes that may predict
late radiotoxicity in heart [32, 33], brain [34], hepatic
[35], and skin [36, 37]. However, to our knowledge, only
few studies measured the basal level of plasma proteins
in patients with non-small cell lung (NSCLC) before
starting RT [38, 39]. The authors showed that the level
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of C4b-binding protein alpha chain, complement C3,
and vitronectin was higher in patients who later devel-
oped grade ≥ 2 radiation-induced lung toxicity than in
patients who did not. By using a bioinformatics ap-
proach, Oh et al. analyzed proteomic data obtained
using plasma from 26 patients with locally advanced
NSCLC, and identified α-2-macroglobulin protein as
predictive biomarker for radiation-induced pneumonitis
[40]. Despite the depletion of the most abundant plasma




Fig. 3 NOX4 mRNA and protein levels are increased in PBMCs after ex-vivo irradiation. a mRNA expression of NOX family members in all patients
(n = 20; n = 7 with and n = 13 without grade≥ 2 bf+) in non-irradiated PBMC samples was analyzed by qRT-PCR. ND, not detected (below
threshold). b NOX4 mRNA expression is increased in all patients (n = 20) at 24 h after irradiation (8 Gy) compared with non-irradiated samples (0
Gy) (Wilcoxon matched-pairs signed rank test). c NOX4 protein expression in all patients (n = 20) at 24 h after irradiation (8 Gy) compared with
non-irradiated samples (0 Gy) (Wilcoxon matched-pairs signed rank test). d Western blot analysis of NOX4 expression in all 20 patients before (−)
and at 24 h after 8 Gy-irradiation (+). β-actin was used as loading control. Data are the mean ± SEM; *p < 0.05 (paired t-test)
A B
Fig. 2 AK2 is differentially expressed between patients with and without grade≥ 2 bf+. a Immunoblot analysis of AK2, ANX1, HSPA8 and IDH2 in
control (0 Gy) and 8 Gy-irradiated T lymphocytes from the indicated patients. β-actin was used as loading control. b Quantification of the
immunoblot presented in A using the ImageJ software. Data are the mean ± SEM; *p < 0.05 (2-tailed Mann-Whitney test). qRT-PCR analysis of AK2
and IDH2 mRNA expression in control (0 Gy) and 8 Gy-irradiated T lymphocytes from the same patients with and without grade≥ 2 bf+. The
graph shows the expression level in irradiated samples relative to non-irradiated samples
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expressed proteins. However, we think that rather than
assessing the protein basal level, the approach of looking at
radiation-induced changes before starting RT is more
promising, as successfully demonstrated by the RILA assay.
Accordingly, in the present study, we used iTRAQ quanti-
tative proteomics to identify lymphocyte proteins that
might predict late radiation-induced toxicity. To this aim,
we first selected proteins that were differentially expressed
between patients with grade ≥ 2 bf + and grade < 2 bf+.
Then, to ensure that the protein expression differences be-
tween groups were induced by radiation, we selected the
proteins for which the four ratios between patients with
grade ≥ 2 bf + and grade < 2 bf + after 8Gy where higher
than the four ratios for the non-irradiated patients’ samples.
Using this approach, we identified 23 proteins, and con-
firmed that among these proteins, AK2 was differentially
expressed in irradiated T lymphocytes from these two
groups of patients. The main function of the mitochondrial
protein AK2 is to monitor the cellular energy state through
nucleotide signaling [41]. Some studies demonstrated that
disturbed adenine nucleotide metabolism may lead to ab-
normal ROS production, and AK2 knockdown or AK2 mu-
tation results in increased ROS levels [42, 43]. Besides AK2,
our proteomic analysis showed that many proteins involved
in oxidative stress homeostasis were differentially expressed
between patients with and without grade ≥ 2 radiotoxicity.
Oxidative stress is a key biochemical event during radiation
exposure, and is often seen as the main mediator of the
deleterious effects of ionizing radiation in cells. Oxidative
changes may continue for days or months after the initial
exposure to radiation, and the persistence of such chronic
stress could explain most of the long-term side effects ob-
served after RT [44]. Therefore, we measured the level of
total ROS and of superoxide anion, the precursor of most
ROS and a mediator in oxidative chain reactions [45]. Total
ROS and particularly superoxide anion were increased in ir-
radiated PBMCs from all patients. NOXs, which are a
major source of superoxide anion in the cell [46, 47], form
a family that includes seven enzymatic complexes (NOX1
to NOX5, DUOX1, and DUOX2). All NOX family mem-
bers transport electrons across biological membranes to re-
duce oxygen to superoxide anion. Recent evidences
indicate that some NOX isoforms are often responsible for
ROS-induced fibroblast activation, and are involved in fi-
brosis development, the main form of radiation-induced
late toxicity [48, 49]. To our knowledge, this is the first
study that compared NOX expression in normal tissue be-
tween patients with and without grade ≥ 2 bf+. We focused
on NOX4 because it was the most abundant isoform in
PBMCs. We found that overall, both NOX4 mRNA and
protein levels were increased after ex-vivo irradiation, sug-
gesting a radiation-induced activation in mononuclear
blood cells. Moreover, NOX4 mRNA level increase (com-
pared with non-irradiated samples) was significant only in
samples from patients with grade ≥ 2 bf+. However, NOX4
mRNA upregulation in patients with grade ≥ 2 bf + was not
correlated with ROS level, and we did not identify any dif-
ference in superoxide anion and total ROS levels between
patients with and without grade ≥ 2 bf+. This could be
linked to the fact that the identity of the reactive oxygen
product of NOX4 is currently a matter of debate. Differ-
ently from NOX1-NOX3 and NOX5 that release super-
oxide anion, some studies reported that H2O2 is the major
product of NOX4, whereas other studies detected also
superoxide anion [50]. Moreover, in samples from patients
with grade ≥ 2 bf+, only NOX4 mRNA and not protein ex-
pression was increased, suggesting that irradiation affects
only NOX4 transcription and not its protein activity. This
A B
Fig. 4 After irradiation (8 Gy), NOX4 mRNA level is significantly increased in PBMCs of patients with grade≥ 2 bf+. a NOX4 mRNA expression
(qRT-PCR analysis) in patients with grade < 2 bf + (n = 13) and with grade≥ 2 bf + (n = 7) before (circles) and at 24 h after 8 Gy-irradiation
(squares). b NOX4 protein expression (western blotting) in patients with grade < 2 bf + (n = 13) and grade≥ 2 bf + (n = 7) before (circles) and at
24 h after 8 Gy-irradiation (squares) (two-way ANOVA with Bonferroni post-tests). NS: Not Significant; *p < 0.05, by paired t-test. Data are
the mean ± SEM
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could explain the absence of effect on ROS production.
The biology of NADPH oxidases is complex and additional
studies are needed to determine its role in late radiotoxicity.
Finally, due to the difficulty to obtain samples from patients
with late radiotoxicity, the limited number of analyzed sam-
ples does not allow clear conclusions about NOX4 role in
individual radiosensitivity. An independent and prospective
validation study with a larger number of patients is
required.
To our knowledge, AK2 has never been directly in-
volved in NOXs regulation. However, among the 23 can-
didate proteins, some contribute to NOX regulation,
such as HSPA8 and APEX1. Indeed, proteins of the
HSP70 family decrease ROS production by the NOX iso-
forms 1, 3, and 5, and bind to NOX2 [51]. APE1 directly
controls the intracellular level of ROS through its inhibi-
tory effect on Rac1, the NOX regulatory subunit [52]. In
our study, we used T cells for the proteomic analysis that
identified AK2, and PBMCs to measure NOX4 level
after irradiation. Therefore, our data cannot be used to
suggest a direct interaction.
Finally, as radiation-induced apoptosis may predict late
toxicity, it is interesting to note that inhibition of AK2
and NOX4 reduces apoptosis [53–58]. Specifically, AK2
mediates mitochondrial apoptosis through the formation
of an AK2–FADD–caspase 10 complex [53, 54], whereas
NOX4-mediated ROS production induces apoptosis in
cancer and normal cells upon stimulation, for instance
by incubation with TNF-α [55], glucose [56], or anti-can-
cer drugs [57, 58]. On the other hand, some studies
showed that cell death is not an intrinsic effect of AK2
deficiency [59], and that NOX4 could inhibit apoptosis
[60, 61]. Our present results suggesting that AK2 protein
and NOX4 mRNA upregulation upon irradiation could
be associated with grade ≥ 2 bf+, and the finding that
high RILA value (indicative of high apoptosis) is not as-
sociated with late radiotoxicity suggest a potential radi-
ation-induced anti-apoptotic effect of these proteins.
However, in order to complement the RILA assay (low
PPV) and identify new toxicity biomarkers, we initially
selected both patients with grade ≥ 2 bf + and < 2 bf +
with low RILA score (≤16%). Therefore, the relationship
between RILA and radiation-induced protein expression
cannot be established based on our data. The relation
between RILA values and predictive biomarkers of radi-
ation-induced late injuries will need to be investigated to
understand the link between clinical outcome and ex-
vivo cellular responses to radiation.
Conclusion
This study describes a new role of AK2 as potential
lymphocyte biomarker of radiation toxicity in patients
with grade ≥ 2 radiation-induced breast fibrosis. It also
showed for the first time that NOX4 is the most
abundant NOX isoform in PBMCs and that its expres-
sion is stimulated by irradiation, thus confirming results
from previous studies [50]. We believe that our findings
could provide new insight into the mechanism under-
lying individual radiosensitivity and the establishment of
late radiation-induced toxicity, and will pave the way to
additional studies.
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